A5039283256- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Renal Transplantation Outcomes and Treatments
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- PI3K/AKT/mTOR signaling in cancer
- Galectins and Cancer Biology
- Polyomavirus and related diseases
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Mesenchymal stem cell research
- Glycosylation and Glycoproteins Research
- Calcium signaling and nucleotide metabolism
- Immunotherapy and Immune Responses
- CNS Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
UNM Comprehensive Cancer Center
2019-2025
New Mexico Cancer Center
2019-2025
University of New Mexico
2018-2025
The Ohio State University
2013-2023
The Ohio State University Wexner Medical Center
2009-2020
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2008-2019
Columbus Center
2014-2016
HistoGenetics (United States)
2014
Brigham and Women's Hospital
2014
University of North Carolina at Chapel Hill
2014
<h3>Importance</h3> The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy this drug and outcomes following discontinuation have not been evaluated outside of clinical trials relatively short follow-up. <h3>Objective</h3> To determine features associated outcomes. <h3>Design, Setting, Participants</h3> A total 308 participating 4 sequential at Ohio State University Comprehensive Cancer Center...
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift therapy, and relapse been uncommon current follow-up. Acquired mutations BTK PLCG2 can cause relapse, but data regarding the prevalence natural history these are limited. Patients Methods accrued four sequential studies were included analyses. Deep sequencing for was performed retrospectively on patients who experienced prospectively screening population....
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell (ITK). The relative importance of these 2 kinases not examined despite its relevance immune-based therapies.
Patients with chronic lymphocytic leukemia (CLL) high-risk genomic features achieve poor outcomes traditional therapies. A phase I study of a pharmacokinetically derived schedule flavopiridol suggested promising activity in CLL, irrespective features. Given the relevance these findings to treating genetically prospective confirmatory was initiated.
Purpose Lenalidomide is a novel therapeutic agent with uncertain mechanism of action that clinically active in myelodysplastic syndrome (MDS) and multiple myeloma (MM). Application high (MM) low doses lenalidomide has been reported to have clinical activity CLL. Herein, we highlight life-threatening tumor flare when higher are administered patients CLL provide potential for its occurrence. Patients Methods Four relapsed were treated (25 mg/d 21 days 28-day cycle). Serious adverse events...
Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management AF this patient population are limited, and stroke prevention poses a challenge because increased risk bleeding with ibrutinib treatment. Our study sought describe incidence adult treated for hematologic malignancy, assess strategies, evaluate outcomes, identify factors occurrence. Of 582 ibrutinib, 76 developed AF. With median follow-up 32 months, estimated cumulative at 6 1...
Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations ARQ 531, a potent, reversible BTK additional activity against Src family kinases and related to ERK signaling. We hypothesized that targeting would improve global signaling pathways, producing more robust responses. In vitro treatment patient CLL...
Tetraspanins are commonly believed to act only as "molecular facilitators," with no direct role in signal transduction. We herein demonstrate that upon ligation, CD37, a tetraspanin molecule expressed on mature normal and transformed B cells, becomes tyrosine phosphorylated, associates proximal signaling molecules, initiates cascade of events leading apoptosis. Moreover, we have identified two residues opposing regulatory functions: one lies the N-terminal domain CD37 predicted "ITIM-like"...
Abstract On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland ), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for treatment children young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era personalized cancer immunotherapy, multiple challenges are present ranging from implementation CAR-T program to safe delivery drug, long-term...
On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for treatment children young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era personalized cancer immunotherapy, multiple challenges are present, ranging from implementation CAR-T program to safe delivery drug, long-term toxicity monitoring,...
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) granulocyte colony-stimulating (G-CSF) promote haematopoietic progenitor cell maturation. We reviewed the findings for healthy volunteers/donors who developed haematological malignancies following PEG-rHuMGDF or G-CSF administration. Information was three of 538 volunteers received in clinical trials two 200 donors underwent mobilised stem harvesting procedures sibling transplants. Mantle cell, diffuse...
Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL). The anti-CD20 antibody rituximab active in CLL and represents rational to combine with lenalidomide. We therefore examined whether lenalidomide combined direct apoptosis ADCC cells. In contrast previous reports using CD20-positive lymphoma cell lines, down-regulated CD20 surface antigen expression patient...
Summary Richter Syndrome, an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia ( CLL ), has a generally poor prognosis and anthracycline‐based chemoimmunotherapy regimens designed to treat de novo diffuse large B‐cell achieve modest clinical benefit. R‐ EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) demonstrated greater activity against histologies but not been studied Syndrome. We conducted retrospective cohort study of 46...